Medindia

X

VAP Cholesterol Test From Atherotech Covers 90 Percent of Arizona Insured

Thursday, February 7, 2008 General News J E 4
Advertisement
BIRMINGHAM, Ala., Feb. 6 Atherotech, Inc., acardio-diagnostic company, today announced that the largest private insurersin Arizona as well as Medicare, Medicaid and the Federal Employees HealthBenefits (FEHB) Program now cover the VAP (Vertical Auto Profile) Test, themost comprehensive cholesterol test available. That means almost 90 percent ofall insured lives in Arizona now have insurance coverage for the VAP Test,which finds twice as many people at risk than the standard cholesterol test.

"The state of Arizona is extremely progressive in preventive health," saidAtherotech Chief Medical Officer James Ehrlich, M.D. "The highly accurate VAPTest allows the clinician to target high-risk patients for specific therapythat could help prevent millions of future heart attacks and strokes. I amconfident that the VAP Test will continue to be regarded as the best and mostcost-effective laboratory method to precisely identify vulnerable individualswho may be at risk for the nation's leading killer, cardiovascular disease."

People with a family history or an existing condition of diabetes, highblood pressure or heart disease -- or who are already taking cholesterollowering medication -- are candidates for the comprehensive VAP Test. Inaddition, those who didn't score within the desirable ranges of the standardcholesterol test (i.e. those with Triglycerides > 150, HDL < 40, LDL >130,Total Cholesterol > 200) should also opt for the more detailed VAP Test.

"The VAP cholesterol test allows a detailed analysis of all lipidparameters to obtain an accurate and predictive risk for CVD," said RichardFowler, M.D., of the Arizona Center for Internal Medicine.

The VAP Test is the first cholesterol test to identify markers forMetabolic Syndrome, a precursor for diabetes. The VAP Test directly andaccurately measures fifteen separate components of blood cholesterol comparedto just three in a standard cholesterol test. This more comprehensive test hasbeen shown to identify over twice the number of patients with lipidabnormalities than the standard lipid panel (cholesterol and triglyceridetest). Risks of both heart disease and diabetes can be reduced with the rightpreventive treatments, which is why more accurate diagnosis is critical.

The VAP Test is available nationwide. Consumers interested in the test canask their doctor for more information or visit http://www.thevaptest.com.Individuals should always check their plan for specific benefit coverage.

About Atherotech, Inc.

Atherotech is a cardio-diagnostic company focusing on direct measurementof the comprehensive lipid panel using the company's VAP Technology.Specifically, the VAP technology is a patented density gradientultracentrifugation that directly measures the cholesterol content of alllipids, components and subclasses. The VAP Test is the first cholesterolprofile to comply with updated National Cholesterol Education Program ATP IIIrecommendations calling for more accurate, direct, low-density lipoprotein(LDL) measurement, which is unaffected by triglycerides. Included inForbes.com's list of "15 ways to Live Longer" and named one of "Five TestsWorth Paying For" by the Wall Street Journal, The VAP Cholesterol Test -- thenew standard of care for patients at risk for cardiovascular disease -- isavailable through national and regional diagnostic laboratories and isreimbursed by many of the largest private insurers as well as Medicare. Formore information, visit http://www.thevaptest.com.

SOURCE Atherotech, Inc.
Advertisement


Advertisement

You May Also Like

Advertisement
View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
s
Molecular Therapy Succeeds in Preventing Craniofac...
S
Margaret Dimond Named President and CEO of McLaren...